$MPLT

Lillie James Woodruff sold $674K of MPLT

Lillie James Woodruff (Chief Scientific Officer) sold 18,267 shares of MapLight Therapeutics, Inc. (MPLT) at an average of $36.88 ($36.00–$37.96, $0.67M total) across 7 trades over 2026-07-15 to 2026-07-17.

Original reporting
SEC EDGAR · Lillie James Woodruff
Published Jul 18, 2026, 1:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 18, 2026, 2:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MPLT
Neutral
medium confidence
Mentioned
$MPLT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MPLTNeutralLow
01

Why it matters

The new information is the disclosed open-market sale amount, share count, and trade dates, which may influence short-term sentiment but does not provide new company performance or guidance.

02

Market read

Traders may monitor for follow-on insider activity or whether the sale coincides with other catalysts, but the filing alone is unlikely to drive a durable repricing.

03

What to watch

The article does not state whether the sale was tax-related, planned for liquidity, or paired with any other insider buying, limiting inference from the transaction alone.

Relevance 5/10Novelty 6/10Timing: after-hours filing on 2026-07-17 for trades executed 2026-07-15 to 2026-07-17

Background

The article is an SEC Form 4 insider transaction disclosure for MapLight Therapeutics, Inc., reported by its Chief Scientific Officer.

Company-level read

Ticker impact

$MPLTNeutralMedium confidence
Context

MapLight Therapeutics CSO Lillie James Woodruff sold $673,636 of MPLT shares in open-market trades dated July 15 to July 17.

Expected impact

Likely limited, short-lived sentiment impact; any move would be small unless accompanied by other company-specific catalysts.

Evidence & confidence

The filing is a Form 4 insider transaction with a defined sale window and price range, but it provides no new operational, clinical, or financial guidance.

Market effects

No direct sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider sales can be routine liquidity events and are not necessarily bearish, especially without a 10b5-1 plan being cited here.

Key entities

  • MapLight Therapeutics, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Lillie James Woodruff

    Chief Scientific Officer who sold shares in open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MPLTMed

MapLight Therapeutics, Inc. (MPLT): Results of Operations and Financial Condition

MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3 ZEPHYR-2 trial Continued advancement of ML-007C-MA in ADP, with enrollment ongoing in the Phase 2 VISTA trial and